135 related articles for article (PubMed ID: 21894003)
1. Endothelin receptor blockade in patients with diabetic nephropathy.
Rabelink TJ; Kohan DE
Contrib Nephrol; 2011; 172():235-242. PubMed ID: 21894003
[TBL] [Abstract][Full Text] [Related]
2. Endothelin antagonists for diabetic and non-diabetic chronic kidney disease.
Kohan DE; Pollock DM
Br J Clin Pharmacol; 2013 Oct; 76(4):573-9. PubMed ID: 23228194
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta-analysis of randomized controlled trials.
Zhou Y; Chi J; Huang Y; Dong B; Lv W; Wang YG
Diabet Med; 2021 Jan; 38(1):e14411. PubMed ID: 33000477
[TBL] [Abstract][Full Text] [Related]
4. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy.
Kohan DE; Pritchett Y; Molitch M; Wen S; Garimella T; Audhya P; Andress DL
J Am Soc Nephrol; 2011 Apr; 22(4):763-72. PubMed ID: 21372210
[TBL] [Abstract][Full Text] [Related]
5. Atrasentan Reduces Albuminuria by Restoring the Glomerular Endothelial Glycocalyx Barrier in Diabetic Nephropathy.
Boels MG; Avramut MC; Koudijs A; Dane MJ; Lee DH; van der Vlag J; Koster AJ; van Zonneveld AJ; van Faassen E; Gröne HJ; van den Berg BM; Rabelink TJ
Diabetes; 2016 Aug; 65(8):2429-39. PubMed ID: 27207530
[TBL] [Abstract][Full Text] [Related]
6. Endothelin antagonist as add-on treatment for proteinuria in diabetic nephropathy: is there light at the end of the tunnel?
Ritz E; Wenzel RR
J Am Soc Nephrol; 2011 Apr; 22(4):593-5. PubMed ID: 21415160
[No Abstract] [Full Text] [Related]
7. Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD).
Andress DL; Coll B; Pritchett Y; Brennan J; Molitch M; Kohan DE
Life Sci; 2012 Oct; 91(13-14):739-42. PubMed ID: 22326504
[TBL] [Abstract][Full Text] [Related]
8. Diabetic nephropathy: Endothelin antagonism for diabetic nephropathy.
Sarafidis PA; Lasaridis AN
Nat Rev Nephrol; 2010 Aug; 6(8):447-9. PubMed ID: 20664627
[No Abstract] [Full Text] [Related]
9. The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy.
Pena MJ; de Zeeuw D; Andress D; Brennan JJ; Correa-Rotter R; Coll B; Kohan DE; Makino H; Perkovic V; Remuzzi G; Tobe SW; Toto R; Parving HH; Sharma S; Corringham T; Sharma K; Heerspink HJL
Diabetes Obes Metab; 2017 May; 19(5):749-753. PubMed ID: 28019071
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy.
Kohan DE; Lambers Heerspink HJ; Coll B; Andress D; Brennan JJ; Kitzman DW; Correa-Rotter R; Makino H; Perkovic V; Hou FF; Remuzzi G; Tobe SW; Toto R; Parving HH; de Zeeuw D
Clin J Am Soc Nephrol; 2015 Sep; 10(9):1568-74. PubMed ID: 26153128
[TBL] [Abstract][Full Text] [Related]
11. Distinct actions of endothelin A-selective versus combined endothelin A/B receptor antagonists in early diabetic kidney disease.
Saleh MA; Pollock JS; Pollock DM
J Pharmacol Exp Ther; 2011 Jul; 338(1):263-70. PubMed ID: 21471190
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial.
Webb DJ; Coll B; Heerspink HJL; Andress D; Pritchett Y; Brennan JJ; Houser M; Correa-Rotter R; Kohan D; Makino H; Perkovic V; Remuzzi G; Tobe SW; Toto R; Busch R; Pergola P; Parving HH; de Zeeuw D
Drugs R D; 2017 Sep; 17(3):441-448. PubMed ID: 28831752
[TBL] [Abstract][Full Text] [Related]
13. Predictors of congestive heart failure after treatment with an endothelin receptor antagonist.
Hoekman J; Lambers Heerspink HJ; Viberti G; Green D; Mann JF; de Zeeuw D
Clin J Am Soc Nephrol; 2014 Mar; 9(3):490-8. PubMed ID: 24408122
[TBL] [Abstract][Full Text] [Related]
14. Atrasentan: The Difficult Task of Integrating Endothelin A Receptor Antagonists into Current Treatment Paradigm for Diabetic Kidney Disease.
Ortiz A; Fernandez-Fernandez B
Clin J Am Soc Nephrol; 2021 Dec; 16(12):1775-1778. PubMed ID: 34853063
[No Abstract] [Full Text] [Related]
15. Atrasentan for the treatment of diabetic nephropathy.
Egido J; Rojas-Rivera J; Mas S; Ruiz-Ortega M; Sanz AB; Gonzalez Parra E; Gomez-Guerrero C
Expert Opin Investig Drugs; 2017 Jun; 26(6):741-750. PubMed ID: 28468519
[TBL] [Abstract][Full Text] [Related]
16. Diuretic medication and change in fluid retention biomarkers during treatment with the endothelin receptor antagonist atrasentan.
Smeijer JD; Kohan DE; de Zeeuw D; Heerspink HJL
Diabetes Obes Metab; 2023 Aug; 25(8):2419-2422. PubMed ID: 37157922
[No Abstract] [Full Text] [Related]
17. Avosentan reduces albumin excretion in diabetics with macroalbuminuria.
Wenzel RR; Littke T; Kuranoff S; Jürgens C; Bruck H; Ritz E; Philipp T; Mitchell A;
J Am Soc Nephrol; 2009 Mar; 20(3):655-64. PubMed ID: 19144760
[TBL] [Abstract][Full Text] [Related]
18. Diabetic nephropathy in 2014: improved cardiorenal prognosis in diabetic nephropathy.
Parving HH; Rossing P
Nat Rev Nephrol; 2015 Feb; 11(2):68-70. PubMed ID: 25488854
[TBL] [Abstract][Full Text] [Related]
19. Effects of endothelin receptor antagonists on the progression of diabetic nephropathy.
Hocher B; Schwarz A; Reinbacher D; Jacobi J; Lun A; Priem F; Bauer C; Neumayer HH; Raschack M
Nephron; 2001 Feb; 87(2):161-9. PubMed ID: 11244312
[TBL] [Abstract][Full Text] [Related]
20. The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice.
Watson AM; Li J; Schumacher C; de Gasparo M; Feng B; Thomas MC; Allen TJ; Cooper ME; Jandeleit-Dahm KA
Diabetologia; 2010 Jan; 53(1):192-203. PubMed ID: 19862499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
